BRPI0411715B8 - composição farmacêutica compreendendo salinosporamidas - Google Patents
composição farmacêutica compreendendo salinosporamidasInfo
- Publication number
- BRPI0411715B8 BRPI0411715B8 BRPI0411715A BRPI0411715A BRPI0411715B8 BR PI0411715 B8 BRPI0411715 B8 BR PI0411715B8 BR PI0411715 A BRPI0411715 A BR PI0411715A BR PI0411715 A BRPI0411715 A BR PI0411715A BR PI0411715 B8 BRPI0411715 B8 BR PI0411715B8
- Authority
- BR
- Brazil
- Prior art keywords
- strains
- cnb476
- salinosporamides
- marine
- salinesporamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
salinosporamidas e métodos para uso das mesmas. a presente invenção refere-se à descoberta de que determinados produtos da fermentação das cepas cnb392 e cnb476 do actinomicete marinho são inibidores eficazes das células hiperproliferativas de mamíferos. as cepas cnb392 e cnb476 estão dentro da família dos micromonosporaceae, e o epíteto genérico salinospora foi proposto para esse grupo de obligatos marinhos. os produtos de reação produzidos por essas cepas são classificados como salinosporamidas, e são especificamente vantajosos para o tratamento de distúrbios neoplásicos, devido ao seu baixo peso molecular, baixos valores de lc50, alta potência farmacêutica, e seletividade para células de câncer sobre os fungos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/600,854 | 2003-06-20 | ||
US10/600,854 US7179834B2 (en) | 2002-06-24 | 2003-06-20 | Salinosporamides and methods for use thereof |
US10/838,157 US7176232B2 (en) | 2002-06-24 | 2004-04-30 | Salinosporamides and methods for use thereof |
US10/838,157 | 2004-04-30 | ||
PCT/US2004/019453 WO2005003137A1 (en) | 2003-06-20 | 2004-06-18 | Salinosporamides and methods for use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0411715A BRPI0411715A (pt) | 2006-08-08 |
BRPI0411715B1 BRPI0411715B1 (pt) | 2020-12-01 |
BRPI0411715B8 true BRPI0411715B8 (pt) | 2021-05-25 |
Family
ID=33568002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411715A BRPI0411715B8 (pt) | 2003-06-20 | 2004-06-18 | composição farmacêutica compreendendo salinosporamidas |
Country Status (9)
Country | Link |
---|---|
US (9) | US7176232B2 (pt) |
EP (1) | EP1638977A4 (pt) |
JP (1) | JP2007523859A (pt) |
KR (1) | KR101183784B1 (pt) |
AU (1) | AU2004253879A1 (pt) |
BR (1) | BRPI0411715B8 (pt) |
CA (1) | CA2530215A1 (pt) |
MX (1) | MXPA05013985A (pt) |
WO (1) | WO2005003137A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4322802A (en) * | 2000-11-16 | 2002-06-24 | Univ California | Marine actinomycete taxon for drug and fermentation product dicovery |
US7176232B2 (en) * | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
CA2532066C (en) * | 2003-06-20 | 2015-07-28 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
CN101791306A (zh) * | 2003-06-20 | 2010-08-04 | 加利福尼亚大学董事会 | 盐孢菌酰胺及其使用方法 |
WO2005074594A2 (en) | 2004-01-30 | 2005-08-18 | Great Lakes Chemical Corporation | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers |
WO2006028525A2 (en) * | 2004-04-30 | 2006-03-16 | Nereus Pharmaceuticals, Inc. | [3.2.0] heterocyclic compounds and methods of using the same |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
CN101155582B (zh) * | 2004-12-03 | 2013-04-24 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的组合物和方法 |
CA2590334A1 (en) * | 2004-12-03 | 2006-06-08 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US20060287520A1 (en) * | 2005-05-16 | 2006-12-21 | Danishefsky Samuel J | Synthesis of salinosporamide A and analogues thereof |
US7572606B1 (en) * | 2005-09-09 | 2009-08-11 | Nereus Pharmaceuticals, Inc. | Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs |
BRPI0618198A2 (pt) * | 2005-11-04 | 2018-06-26 | Nereus Pharmaceuticals Inc | métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia |
DE202006002452U1 (de) * | 2006-02-16 | 2006-05-24 | Lanxess Deutschland Gmbh | Formkörper für den Sanitärbereich |
BRPI0709474A2 (pt) * | 2006-04-06 | 2011-07-12 | Nerus Pharmaceuticals Inc | sìntese total de salinosporamida a e seus análogos |
US8986971B2 (en) | 2006-09-22 | 2015-03-24 | Triphase Research And Development I Corp. | Salt formulations for the fermentation of marine microorganisms |
US7824698B2 (en) * | 2007-02-02 | 2010-11-02 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of Salinosporamide A |
US20080280968A1 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US8318656B2 (en) | 2007-07-03 | 2012-11-27 | E. I. Du Pont De Nemours And Company | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
BRPI0909661A2 (pt) | 2008-03-07 | 2015-08-11 | Nereus Pharmaceuticals Inc | Composto e métodos de síntese química e de formação ou preparação de compostos |
US20090285836A1 (en) * | 2008-04-14 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Use of salinosporamide a to inhibit metastasis |
CA2723465A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
EP2399129B1 (en) | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
CA2862580A1 (en) | 2011-10-28 | 2013-05-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to nae inhibitors |
US20150184246A1 (en) | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
US20160008382A1 (en) | 2012-01-24 | 2016-01-14 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
WO2013112881A1 (en) | 2012-01-27 | 2013-08-01 | Thomas Jefferson University | Mct protein inhibitor-related prognostic and therapeutic methods |
CN104822844B (zh) | 2012-10-01 | 2019-05-07 | 米伦纽姆医药公司 | 预测对抑制剂的反应的生物标记物和方法以及其用途 |
EP2986290A4 (en) | 2013-04-19 | 2017-01-04 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
CN103408503B (zh) * | 2013-08-21 | 2015-03-11 | 中国科学院南海海洋研究所 | 一种生物碱类化合物的制备方法及其在制备抑制钙离子通道药物中的应用 |
JP7171550B2 (ja) | 2016-06-01 | 2022-11-15 | セルジュヌ アンテルナシオナル ドゥジエム ソシエテ ア レスポンサビリテ リミティー | 中枢神経系(cns)がんの処置のためのマリゾミブの使用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5276182A (en) | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
DE4028102A1 (de) | 1990-09-05 | 1992-03-12 | Metallgesellschaft Ag | Verfahren zur analyse von metallteilchen |
DE4030414A1 (de) | 1990-09-26 | 1992-04-02 | Winkler Duennebier Kg Masch | Verfahren zum herstellen von selbstklebeumschlaegen |
DE4039602A1 (de) | 1990-12-12 | 1992-06-17 | Bauer Kurt Heinz Prof Dr | Pharmazeutische formulierungen |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
US5683676A (en) | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
CA2308082A1 (en) | 1992-11-27 | 1994-06-09 | Paul Handreck | Injectable compostion |
US5654286A (en) | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
JP3844491B2 (ja) | 1993-10-01 | 2006-11-15 | シンテックス(ユー・エス・エイ)インコーポレイテッド | ミコフェノール酸モフェチル高用量経口用懸濁剤 |
US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6838477B2 (en) | 1995-04-12 | 2005-01-04 | President And Fellows Of Harvard College | Lactacystin analogs |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5653987A (en) | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
CN1159061C (zh) | 1997-02-15 | 2004-07-28 | 千年药物公司 | 通过nf-kappab的抑制治疗梗塞 |
US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
CN1137878C (zh) | 1997-08-04 | 2004-02-11 | 大正制药株式会社 | 芳氧基苯胺衍生物 |
CA2301054A1 (en) | 1997-08-15 | 1999-02-25 | Francois Soucy | Synthesis of clasto-lactacystin .beta.-lactone and analogs thereof |
US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
US20010051654A1 (en) | 1997-09-25 | 2001-12-13 | Elliott Peter J. | Treatment of inflammatory and autoimmune diseases |
EP1017398A1 (en) | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
US6479484B1 (en) | 1997-11-21 | 2002-11-12 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
JP3794469B2 (ja) | 1998-03-26 | 2006-07-05 | 塩野義製薬株式会社 | 抗ウイルス作用を有するインドール誘導体 |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
NZ511197A (en) | 1998-10-20 | 2003-08-29 | Millenium Pharmaceuticals Inc | Method for monitoring proteasome inhibitor drug action |
FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20020049157A1 (en) | 1999-08-25 | 2002-04-25 | Jiangping Wu | Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
DK1326632T3 (da) | 2000-10-12 | 2007-01-15 | Viromics Gmbh | Protease-inhibitorer til behandling af infektioner af hepatitisvirus |
AU4322802A (en) | 2000-11-16 | 2002-06-24 | Univ California | Marine actinomycete taxon for drug and fermentation product dicovery |
DE10391147D2 (de) | 2002-04-05 | 2005-02-17 | Viromics Gmbh | Mittel zur Behandlung von Flaviviridae-Infektionen |
US7179834B2 (en) | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
JP5354836B2 (ja) | 2002-11-06 | 2013-11-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | プロテアソームインヒビターを使用する癌を処置するための方法および組成物 |
EP1597262B1 (en) | 2003-02-14 | 2009-11-11 | InterMed Discovery GmbH | Substituted heterocycles |
CA2532066C (en) * | 2003-06-20 | 2015-07-28 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
CN101791306A (zh) | 2003-06-20 | 2010-08-04 | 加利福尼亚大学董事会 | 盐孢菌酰胺及其使用方法 |
WO2005094423A2 (en) | 2004-02-26 | 2005-10-13 | President And Fellows Of Harvard College | Selective inhibition of proteasomes of tuberculosis and other bacteria |
US7371875B2 (en) * | 2004-03-12 | 2008-05-13 | Miikana Therapeutics, Inc. | Cytotoxic agents and methods of use |
US7183417B2 (en) * | 2004-04-09 | 2007-02-27 | President And Fellows Of Harvard College | Simple stereocontrolled synthesis of salinosporamide A |
WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US20060264495A1 (en) | 2004-04-30 | 2006-11-23 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
WO2006028525A2 (en) * | 2004-04-30 | 2006-03-16 | Nereus Pharmaceuticals, Inc. | [3.2.0] heterocyclic compounds and methods of using the same |
US7579371B2 (en) * | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
WO2006005551A1 (en) | 2004-07-12 | 2006-01-19 | Bayer Cropscience Ag | Substituted 2-pyrrolidone derivatives as fungicides and insecticides |
WO2006060609A1 (en) | 2004-12-03 | 2006-06-08 | Honeywell International Inc. | Gas jet control for inertial measurement unit |
WO2006060819A2 (en) | 2004-12-03 | 2006-06-08 | The Regents Of The University Of California | Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells |
CN101155582B (zh) | 2004-12-03 | 2013-04-24 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的组合物和方法 |
CA2590334A1 (en) | 2004-12-03 | 2006-06-08 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
WO2006118973A2 (en) | 2005-04-29 | 2006-11-09 | Nereus Pharmaceuticals, Inc. | Methods of using heterobyclic compounds for treatment of rectal cancer |
US20060287520A1 (en) | 2005-05-16 | 2006-12-21 | Danishefsky Samuel J | Synthesis of salinosporamide A and analogues thereof |
EP1931679A4 (en) | 2005-08-10 | 2009-07-29 | Harvard College | ANALOGUE OF SALINOSPORAMIDE A |
US7572606B1 (en) | 2005-09-09 | 2009-08-11 | Nereus Pharmaceuticals, Inc. | Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs |
US7465720B2 (en) | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
BRPI0618198A2 (pt) | 2005-11-04 | 2018-06-26 | Nereus Pharmaceuticals Inc | métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia |
EP1979487A4 (en) * | 2006-01-26 | 2010-05-05 | Bebaas Inc | COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER |
GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
BRPI0709474A2 (pt) | 2006-04-06 | 2011-07-12 | Nerus Pharmaceuticals Inc | sìntese total de salinosporamida a e seus análogos |
WO2007130404A1 (en) | 2006-05-03 | 2007-11-15 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
US8088923B2 (en) | 2006-07-07 | 2012-01-03 | The Texas A&M University System | Cyclic-fused beta-lactones and their synthesis |
WO2008124699A1 (en) | 2007-04-06 | 2008-10-16 | Nereus Pharmaceuticals, Inc. | A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer |
US20080280968A1 (en) | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US7442830B1 (en) * | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
BRPI0909661A2 (pt) | 2008-03-07 | 2015-08-11 | Nereus Pharmaceuticals Inc | Composto e métodos de síntese química e de formação ou preparação de compostos |
CA2723465A1 (en) | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
-
2004
- 2004-04-30 US US10/838,157 patent/US7176232B2/en not_active Expired - Lifetime
- 2004-06-18 MX MXPA05013985A patent/MXPA05013985A/es active IP Right Grant
- 2004-06-18 AU AU2004253879A patent/AU2004253879A1/en not_active Abandoned
- 2004-06-18 KR KR1020057024462A patent/KR101183784B1/ko active IP Right Grant
- 2004-06-18 BR BRPI0411715A patent/BRPI0411715B8/pt active IP Right Grant
- 2004-06-18 JP JP2006517371A patent/JP2007523859A/ja active Pending
- 2004-06-18 WO PCT/US2004/019453 patent/WO2005003137A1/en active Application Filing
- 2004-06-18 EP EP04776728A patent/EP1638977A4/en not_active Withdrawn
- 2004-06-18 CA CA002530215A patent/CA2530215A1/en not_active Abandoned
-
2005
- 2005-06-07 US US11/147,622 patent/US7176233B2/en not_active Expired - Lifetime
-
2007
- 2007-02-12 US US11/705,694 patent/US7635712B2/en not_active Expired - Lifetime
-
2009
- 2009-12-15 US US12/638,860 patent/US8222289B2/en not_active Expired - Fee Related
-
2012
- 2012-05-22 US US13/477,364 patent/US8637565B2/en not_active Expired - Lifetime
-
2013
- 2013-12-23 US US14/139,692 patent/US9078881B2/en not_active Expired - Lifetime
-
2015
- 2015-07-08 US US14/794,468 patent/US9713607B2/en not_active Expired - Lifetime
-
2017
- 2017-07-20 US US15/655,739 patent/US10314818B2/en not_active Expired - Lifetime
-
2019
- 2019-05-21 US US16/418,801 patent/US10912764B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7176232B2 (en) | 2007-02-13 |
KR20060069793A (ko) | 2006-06-22 |
US7176233B2 (en) | 2007-02-13 |
KR101183784B1 (ko) | 2012-09-17 |
US20170319546A1 (en) | 2017-11-09 |
US10314818B2 (en) | 2019-06-11 |
BRPI0411715B1 (pt) | 2020-12-01 |
US20120230972A1 (en) | 2012-09-13 |
US9078881B2 (en) | 2015-07-14 |
US20040259856A1 (en) | 2004-12-23 |
WO2005003137A1 (en) | 2005-01-13 |
US20190269651A1 (en) | 2019-09-05 |
BRPI0411715A (pt) | 2006-08-08 |
US20070155815A1 (en) | 2007-07-05 |
US8637565B2 (en) | 2014-01-28 |
US7635712B2 (en) | 2009-12-22 |
EP1638977A1 (en) | 2006-03-29 |
EP1638977A4 (en) | 2008-07-23 |
AU2004253879A1 (en) | 2005-01-13 |
US10912764B2 (en) | 2021-02-09 |
US9713607B2 (en) | 2017-07-25 |
US20100144826A1 (en) | 2010-06-10 |
JP2007523859A (ja) | 2007-08-23 |
MXPA05013985A (es) | 2006-03-17 |
US20150313875A1 (en) | 2015-11-05 |
CA2530215A1 (en) | 2005-01-13 |
US20050239866A1 (en) | 2005-10-27 |
US8222289B2 (en) | 2012-07-17 |
US20140178354A1 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411715B8 (pt) | composição farmacêutica compreendendo salinosporamidas | |
BRPI0608402A2 (pt) | compostos de flavonóide e usos dos mesmos | |
BRPI0712631B8 (pt) | compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações | |
CY1114340T1 (el) | Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας | |
BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
UY30759A1 (es) | Compuestos quimicos | |
BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
BRPI0922220B8 (pt) | uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos | |
WO2007138116A3 (de) | Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus | |
BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
BRPI0512986A (pt) | novos derivados de hidantoìna | |
BRPI0613859A8 (pt) | compostos derivados de nitrocatecol, seu uso e seu processo de preparação, bem como composição farmacêutica | |
BRPI0511466A (pt) | agonistas peptìdicos do receptor de vasopressina | |
BRPI0518898A2 (pt) | composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto | |
BR112014012358A2 (pt) | 2-oxo-1,3-dioxolano-4-carboxamidas, sua preparação e uso | |
BRPI1011540A2 (pt) | anticorpos anticxcr4 para o tratamento de of hiv | |
ECSP066822A (es) | Macrólidos y métodos para producir los mismos | |
BR112013006265A2 (pt) | espectros antibióticos gerais análogos a arilomicina | |
BRPI0920621A8 (pt) | Processo para síntese de compostos macrolidos | |
BRPI0508177A (pt) | composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação | |
BRPI0714553B8 (pt) | derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso | |
BR0313043A (pt) | Conjugados efetores, processo para sua produção e seu uso farmacêutico | |
BRPI0607701A2 (pt) | composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto | |
BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
BRPI0812432B8 (pt) | extrusados, seu uso, e medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal: appeal against refusal | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |